Fig. 4: Transcriptomic profiling of post-apalutamide samples and effects of apalutamide treatment on androgen receptor activity. | Prostate Cancer and Prostatic Diseases

Fig. 4: Transcriptomic profiling of post-apalutamide samples and effects of apalutamide treatment on androgen receptor activity.

From: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer

Fig. 4

A Gene expression differences between biochemical responders and non-responders for several AR signalling pathway genes. P-values were obtained from Wilcoxon rank-sum tests. B Gene-set enrichment analysis between biochemical non-responders relative to responders showed an increase in MYC target pathways and androgen response, while immune pathways were downregulated in non-responders after treatment by apalutamide. C Log2 fold change between post-apalutamide and pre-treatment samples for genes involved in AR activity. Samples are split by biochemical response and ordered by baseline AR activity. Log2 fold change are shown from blue to red as indicated by the colour bar. D There is an overall decrease in AR activity after apalutamide, and non-responders had significantly less pronounced decrease in AR activity. P-value was from Wilcoxon rank-sum test comparing the differences in normalised AR activity after treatment between non-responders and responders.

Back to article page